List of patents

Activator of type II pneumocytes
(Patent No. 5451703)
Details We demonstrated that oral administration of LFK increases the number of type II pneumocytes, which act as alveolar epithelial stem cells. Influenza virus infection causes damage to the alveolar epithelial cells. The damage results in disturbances in fluidity at the alveolar-capillary border, which is associated with gas exchange inefficiency and pulmonary vascular permeability. It suggests that LFK might have the effect of improving respiratory function and epithelial barrier function by enhancing proliferation and differentiation of type II pneumocyte during viral infection.
Current treatment and its side effects Vaccination is the primary means to protect from influenza virus infection, but this vaccination strategy can be limited by the production time of vaccine. The antiviral drugs have been approved for the prevention and treatment of influenza. However, the effectiveness of these antiviral agents may be limited by the rapid emergence of drug-resistant viruses.
Anti-pigmentation agent
(Patent No. 4326905)
Details After UV-irradiation to the shaved guinea pigs, the color of skin was monitored over time using color-difference meter. Melanism (sunburn and pigmentation) of the skin was suppressed approximately 30% in LFK administered guinea pigs compared to control ones.
Current treatment and its side effects Rubbing sunblock cream into skin are general way to protect from sunburn. But there is possibility of a cause of inflammation for children and persons with the delicate skin. Vitamin-C, L-cysteine and hythiol-C are well known as ingestible agents to prevent the pigmentaion.
Protection agent on infection
Patent No. 2969017
Details Immune-suppressed mice, which were generated by the dose of anti-tumor or immune-suppressive agents, were infected with Candida albicans after FK-23 administration. Survival rate of these FK-23 administered mice was raised comparing to control mice. It was confirmed that FK-23 has anti-pathogenic infection effects.
Current treatment and its side effects Immune-depression or suppression by aging, diabetes, or side effects of anticancer drugs raises the risk of opportunistic infections such as candida
Therapeutic agent on hepatitis C
(Patent No. 2712000)
Details Oral administration of FK-23 to hepatitis C patients drastically improved their liver functions. FK-23 is expected to suppress the development of liver cancer.
Current treatment and its side effects It is said that there are over 2.5 million of hepatitis C virus carriers in Japan. Hepatitis C is seldom recovered spontaneously and prone to develop into chronic hepatitis, hepatic cirrhosis, and/or liver cancer. However there is no definitive treatment for hepatitis C currently.
Alleviation agent of toxicity
(Patent No. 3040699)
Details In mice experiments, the body weight loss and functional impairment of kidney which were induced by cisplatin (one of most outstanding anticancer drugs) were suppressed by the oral administration of FK-23.
Current treatment and its side effects Current anticancer drugs have strong effect against not only cancer cells but also normal cells and our bodies. Due to this side effect, sufficient outcome has not been acquired. A massive dose or prolonged administration of cisplatin cause the death of kidney cells, and a strong toxicity is shown against other organs if kidney cells are injured. For these reasons, safe and low-toxic alleviation agents for the cisplatin-induced toxicity, which do not attenuate the desired effect of the anticancer drug or reduce the burden on other organs, are requisite.
Anti-tumor agent and its manufacturing process
(Patent No. 3040711)
Details Breast cancer cells were implanted into mice and FK-23 was orally administered to these mice for successive days starting the day after the implantation. Reduction in the size of cancer was observed in FK-23 administered mice compared to control mice. No side effect was observed.
Current treatment and its side effects Current therapies for cancer are surgical treatments, radiation treatments, and chemotherapy. But these treatments have severe side effects. Immune cells such as leukocytes are responsible for eliminating cancer cells. Substances that enhance this eliminating activity are called immunotherapy agents, and many pharmaceutical companies and institutions are competing to discover and develop these agents.
Anti-hypertensive agent
(Patent No. 2889481)
Details Oral administration of FK-23 reduced the blood pressure in spontaneously hypertensive rats.
We identified that the RNA fraction isolated from lysed FK-23 had anti-hypertensive activity.
Current treatment and its side effects Hypertension is a reason for severe diseases such as arteriosclerosis and myocardial and cerebral infarctions. The prolonged administration of anti-hypertensive drugs is necessary for current treatments for hypertension, which brings many problems such as side effects.
Therefore, anti-hypertensive agents without side effects are required to be developed.
Therapeutic agent on rosacea
(Patent No. 2944662)
Details LFK was administered to fourteen patients to whom minocycline as symptomatic treatment was not effective. Ten of these patients improved the rosacea. Any deterioration of the symptom and any appearance of side effects were not observed.
Current treatment and its side effects Rosacea is a chronic symptom characterized by face erythema, which is observed in persons of middle age or older. There is no fundamental treatment against the rosacea, and this symptom is a cosmetic problem.
Anti-allergic agent and its manufacturing process
(Patent No. 3040744)
Details Oral administration of LFK to allergic model mice suppressed the allergic symptoms at the same level as anti-histamine agent (ketotifen). The combined administration of LFK and ketotifen enhanced the suppression activity against the symptoms.
Current treatment and its side effects The number of patients suffering from allergic diseases has been increased. Especially, the number of patients with immediate allergies such as allergic rhinitis, hay fever and allergic dermatitis has been increased. An anti-histamine agent suppresses these allergic symptoms. However, the anti-histamine agent not only suppresses the allergic reactions but also affects the central nervous systems, which causes the side effects such as sleepiness and physical weariness. These side effects often disturb daily activities. Other anti-allergic agents also cause side effects such as the damages to liver and cardiovascular system, and these side effects make patients cancel the administration.
Therapeutic agent on leukocyte reduction
(Patent No. 3272023)
Details In dogs experiment, oral administration of FK-23 suppressed the anticancer drug-induced leukocyte reduction and death.
Current treatment and its side effects Treatment with anticancer drugs attacks on not only cancer cells but also normal cells. The treatment reduces the number of leukocytes, which causes a pathogenic infection and a death in the worst case. Anti-tumor agents with no side effects and drugs to suppress the anticancer drug-induced side effects are expected be developed.